Long-term safety and efficacy of renin–angiotensin blockade in atherosclerotic renal artery stenosis | springermedicine.com

Springer Medicine

Top

International Urology and Nephrology

Published in:

01-10-2012 | Nephrology - Original Paper

Long-term safety and efficacy of renin–angiotensin blockade in atherosclerotic renal artery stenosis

Authors: Sofia Sofroniadou, Theodoros Kassimatis, Rajaventhan Srirajaskanthan, John Reidy, David Goldsmith

Published in: International Urology and Nephrology | Issue 5/2012

Login to get access

Abstract

Purpose

The activation of the renin–angiotensin–aldosterone system caused by renal ischaemia in atherosclerotic renal artery stenosis (ARAS) may be responsible for serious cardiovascular and renal consequences. The aim of the study was to assess the long-term safety, tolerability and outcomes of the use of angiotensin I-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in patients with ARAS.

Methods

Thirty-six patients with angiographically defined ARAS (managed either with revascularization or only with medical treatment) were prospectively assessed for the safety, tolerability and outcomes of the use of ACEis or ARBs.

Results

The mean period of follow-up was 88.9 ± 37.8 months. A statistically significant reduction in systolic and diastolic blood pressure was recorded over time (P < 0.001). While estimated glomerular filtration rate remained almost stable during the study period (0.816), nuclear EDTA-GFR showed a significant reduction over time (P = 0.03). Mean time from diagnosis/intervention to end-stage renal disease for the cohort of 36 patients was 165.38 ± 13.62 months. Mean overall patient survival was 135.36 ± 15.25 months, with fourteen deaths (38.8%) occurring during the observational period. ACEi/ARB therapy was discontinued transiently in only 4 subjects.

Conclusions

The use of ACEis/ARBs is safe and effective in patients with ARAS independently of any parameters.

1.

Derkx FH, Schalekamp MA (1994) Renal artery stenosis and hypertension. Lancet 344:237–239PubMedCrossRef

2.

Ram CV (1997) Renovascular hypertension. Curr Opin Nephrol Hypertens 6:575–579PubMedCrossRef

3.

Hansen KJ, Edwards MS, Craven TE, Cherr GS, Jackson SA, Appel RG et al (2002) Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg 36:443–451PubMedCrossRef

4.

Olin JW, Melia M, Young JR, Graor RA, Risius B (1990) Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 88:46N–51NPubMedCrossRef

5.

Valentine RJ, Clagett GP, Miller GL, Myers SI, Martin JD, Chervu A (1993) The coronary risk of unsuspected renal artery stenosis. J Vasc Surg 18:433–440PubMedCrossRef

6.

Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC et al (2005) Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int 68:293–301PubMedCrossRef

7.

Conlon PJ, Little MA, Pieper K, Mark DB (2001) Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int 60:1490–1497PubMedCrossRef

8.

Mui KW, Sleeswijk M, van den Hout H, van Baal J, Navis G, Woittiez AJ (2006) Incidental renal artery stenosis is an independent predictor of mortality in patients with peripheral vascular disease. J Am Soc Nephrol 17:2069–2074PubMedCrossRef

9.

ASTRAL Investigators, Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson A, Scoble J (2009) Revascularization versus medical therapy for renal artery stenosis. N Engl J Med 361:1953–1962

10.

Iwanaga Y, Kihara Y, Inagaki K, Onozawa Y, Yoneda T, Kataoka K et al (2001) Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation 104:606–612PubMedCrossRef

11.

Yamazaki T, Shiojima I, Komuro I, Nagai R, Yazaki Y (1994) Involvement of the renin-angiotensin system in the development of left ventricular hypertrophy and dysfunction. J Hypertens Suppl 12:S153–S157PubMed

12.

The HOPE Study Investigators (1996) The HOPE (Heart Outcomes Prevention Evaluation) study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 12:127–137

13.

Goldsmith DJ, Reidy J, Scoble J (2000) Renal arterial intervention and angiotensin blockade in atherosclerotic nephropathy. Am J Kidney Dis 36:837–843PubMed

14.

Tullis MJ, Caps MT, Zierler RE, Bergelin RO, Polissar N, Cantwell-Gab K et al (1999) Blood pressure, antihypertensive medication, and atherosclerotic renal artery stenosis. Am J Kidney Dis 33:675–681PubMedCrossRef

15.

Franklin SS, Smith RD (1986) A comparison of enalapril plus hydrochlorothiazide with standard triple therapy in renovascular hypertension. Nephron 44(suppl 1):73–82PubMedCrossRef

16.

Tillman DM, Malatino LS, Cumming AM, Hodsman GP, Leckie BJ, Lever AF et al (1984) Enalapril in hypertension with renal artery stenosis: long-term follow-up and effects on renal function. J Hypertens Suppl 2:S93–S100PubMed

17.

Hodsman GP, Brown JJ, Cumming AM, Davies DL, East BW, Lever AF et al (1983) Enalapril (MK421) in the treatment of hypertension with renal artery stenosis. J Hypertens 1(suppl):109–117

18.

Reams GP, Bauer JH (1985) Enalapril versus triple-drug therapy in the treatment of renovascular hypertension. Drugs 30(suppl 1):59–69PubMedCrossRef

19.

Khosla S, Ahmed A, Siddiqui M, Trivedi A, Benatar D, Salem Y (2006) Safety of angiotensin-converting enzyme inhibitors in patients with bilateral renal artery stenosis following successful renal artery stent revascularization. Am J Ther 13:306–308PubMedCrossRef

20.

Losito A, Errico R, Santirosi P, Lupattelli T, Scalera GB, Lupattelli L (2005) Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transpl 20:1604–1609CrossRef

21.

Hackam DG, Duong-Hua ML, Mamdani M, Li P, Tobe SW, Spence JD, Garg AX (2008) Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J 156:549–555PubMedCrossRef

Title: Long-term safety and efficacy of renin–angiotensin blockade in atherosclerotic renal artery stenosis
Authors: Sofia Sofroniadou
Theodoros Kassimatis
Rajaventhan Srirajaskanthan
John Reidy
David Goldsmith
Publication date: 01-10-2012
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 5/2012
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-011-0091-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties